Using polygenic risk scores of serum CRP and the design of Mendelian randomization, the genetic propensity to higher serum CRP was associated with a reduced risk of schizophrenia and prostate cancer, as well as an increased risk of chronic obstructive pulmonary disease. The gene discussed is CRP; the disease is prostate cancer.